Clinical Trials for Kidney Cancer

The Kidney Cancer Research Consortium brings together some of the nation’s best researchers in clinical kidney cancer trials, enabling multi-site studies at a greatly reduced cost.

The collaborative nature of the Consortium also improves trial enrollment numbers and access to underserved populations of patients. The KCRC includes some of the highest volume renal cell carcinoma clinical trial sites in the country.

Open Trials

Ipilimumab, Nivolumab, and Ciforadenant as First-Line Therapy for Stage IV Renal Cell Carcinoma

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Carcinoma

Upcoming Trials

A phase II study Bolstering outcomes by optimizing immunotherapy strategies with evolocumab and nivolumab in patients with metastatic renal cell carcinoma (BOOST-RCC)

A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in renal cell carcinoma patients with brain metastasis previously treated with immune checkpoint blockade

KCRC LEAP Trial - Kidney Cancer Research Consortium

Closed to Enrollment

Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

Kidney Cancer Research Consortium - Patient Information for Clinical Trials

Information for Patients

Patients with kidney cancer may benefit from participation in clinical trials at any point in their treatment. Read on for more information and to locate enrolling trials.

Kidney Cancer Research News - Kidney Cancer Research Consortium

Research News

Kidney cancer research is a rapidly-advancing area of oncology. Read about the latest research coming from Consortium sites and others researching treatment for RCC.

The Kidney Cancer Research Consortium Members

The Consortium members have over 100 years of combined experience in kidney cancer clinical research. KCRC brings an unmatched commitment to and expertise to RCC trials.

The Latest Tweets from Consortium Investigators:

Load More